BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 31003587)

  • 1. Global Brain Transcriptome Analysis of a Tpp1 Neuronal Ceroid Lipofuscinoses Mouse Model.
    Domowicz MS; Chan WC; Claudio-Vázquez P; Henry JG; Ware CB; Andrade J; Dawson G; Schwartz NB
    ASN Neuro; 2019; 11():1759091419843393. PubMed ID: 31003587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel CLN2/TPP1 mutation in a patient with late infantile neuronal ceroid lipofuscinosis.
    Yu F; Liu XM; Chen YH; Zhang SQ; Wang K
    Neurol Sci; 2015 Oct; 36(10):1917-9. PubMed ID: 26032578
    [No Abstract]   [Full Text] [Related]  

  • 3. Mutation update: Review of TPP1 gene variants associated with neuronal ceroid lipofuscinosis CLN2 disease.
    Gardner E; Bailey M; Schulz A; Aristorena M; Miller N; Mole SE
    Hum Mutat; 2019 Nov; 40(11):1924-1938. PubMed ID: 31283065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multifocal retinopathy in Dachshunds with CLN2 neuronal ceroid lipofuscinosis.
    Whiting RE; Pearce JW; Castaner LJ; Jensen CA; Katz RJ; Gilliam DH; Katz ML
    Exp Eye Res; 2015 May; 134():123-32. PubMed ID: 25697710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain transcriptome analysis of a CLN2 mouse model as a function of disease progression.
    Domowicz MS; Chan WC; Claudio-Vázquez P; Gonzalez T; Schwartz NB
    J Neuroinflammation; 2021 Nov; 18(1):262. PubMed ID: 34749772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene symbol: TPP1. Disease: Neuronal Ceroid Lipofuscinosis, late infantile.
    Kohan R; Muller VJ; Fietz MJ; Cismondi AI; Oller Ramírez AM; Halac IN
    Hum Genet; 2008 Jun; 123(5):553. PubMed ID: 20960655
    [No Abstract]   [Full Text] [Related]  

  • 7. Inducible transgenic expression of tripeptidyl peptidase 1 in a mouse model of late-infantile neuronal ceroid lipofuscinosis.
    Nemtsova Y; Wiseman JA; El-Banna M; Lobel P; Sleat DE
    PLoS One; 2018; 13(2):e0192286. PubMed ID: 29408933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel CLN2/TPP1 mutation in a Chinese patient with late infantile neuronal ceroid lipofuscinosis.
    Wang YL; Zeng ZY; Song XW; Hao ZF; Shi YW; Tang B; Chen SQ; Gao MM; Di W; Long YS; Yi YH; Liao WP
    Neurogenetics; 2011 Feb; 12(1):93-5. PubMed ID: 20820830
    [No Abstract]   [Full Text] [Related]  

  • 9. Homozygous missense TPP1 mutation associated with mild late infantile neuronal ceroid lipofuscinosis and the genotype-phenotype correlation.
    Chen ZR; Liu DT; Meng H; Liu L; Bian WJ; Liu XR; Zhu WW; He Y; Wang J; Tang B; Su T; Yi YH
    Seizure; 2019 Jul; 69():180-185. PubMed ID: 31059981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrathecal tripeptidyl-peptidase 1 reduces lysosomal storage in a canine model of late infantile neuronal ceroid lipofuscinosis.
    Vuillemenot BR; Katz ML; Coates JR; Kennedy D; Tiger P; Kanazono S; Lobel P; Sohar I; Xu S; Cahayag R; Keve S; Koren E; Bunting S; Tsuruda LS; O'Neill CA
    Mol Genet Metab; 2011 Nov; 104(3):325-37. PubMed ID: 21784683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protracted late infantile ceroid lipofuscinosis due to TPP1 mutations: Clinical, molecular and biochemical characterization in three sibs.
    Di Giacopo R; Cianetti L; Caputo V; La Torraca I; Piemonte F; Ciolfi A; Petrucci S; Carta C; Mariotti P; Leuzzi V; Valente EM; D'Amico A; Bentivoglio A; Bertini E; Tartaglia M; Zampino G
    J Neurol Sci; 2015 Sep; 356(1-2):65-71. PubMed ID: 26143525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulation of tripeptidyl-peptidase 1 by 3-hydroxy-(2,2)-dimethyl butyrate, a brain endogenous ligand of PPARα: Implications for late-infantile Batten disease therapy.
    Chakrabarti S; Chandra S; Roy A; Dasarathi S; Kundu M; Pahan K
    Neurobiol Dis; 2019 Jul; 127():362-373. PubMed ID: 30928643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autosomal recessive spinocerebellar ataxia 7 (SCAR7) is caused by variants in TPP1, the gene involved in classic late-infantile neuronal ceroid lipofuscinosis 2 disease (CLN2 disease).
    Sun Y; Almomani R; Breedveld GJ; Santen GW; Aten E; Lefeber DJ; Hoff JI; Brusse E; Verheijen FW; Verdijk RM; Kriek M; Oostra B; Breuning MH; Losekoot M; den Dunnen JT; van de Warrenburg BP; Maat-Kievit AJ
    Hum Mutat; 2013 May; 34(5):706-13. PubMed ID: 23418007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human iPSC models of neuronal ceroid lipofuscinosis capture distinct effects of TPP1 and CLN3 mutations on the endocytic pathway.
    Lojewski X; Staropoli JF; Biswas-Legrand S; Simas AM; Haliw L; Selig MK; Coppel SH; Goss KA; Petcherski A; Chandrachud U; Sheridan SD; Lucente D; Sims KB; Gusella JF; Sondhi D; Crystal RG; Reinhardt P; Sterneckert J; Schöler H; Haggarty SJ; Storch A; Hermann A; Cotman SL
    Hum Mol Genet; 2014 Apr; 23(8):2005-22. PubMed ID: 24271013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Batten disease: biochemical and molecular characterization revealing novel PPT1 and TPP1 gene mutations in Indian patients.
    Sheth J; Mistri M; Bhavsar R; Pancholi D; Kamate M; Gupta N; Kabra M; Mehta S; Nampoothiri S; Thakker A; Jain V; Shah R; Sheth F
    BMC Neurol; 2018 Dec; 18(1):203. PubMed ID: 30541466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): Expert recommendations for early detection and laboratory diagnosis.
    Fietz M; AlSayed M; Burke D; Cohen-Pfeffer J; Cooper JD; Dvořáková L; Giugliani R; Izzo E; Jahnová H; Lukacs Z; Mole SE; Noher de Halac I; Pearce DA; Poupetova H; Schulz A; Specchio N; Xin W; Miller N
    Mol Genet Metab; 2016 Sep; 119(1-2):160-7. PubMed ID: 27553878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CLN2 Disease (Classic Late Infantile Neuronal Ceroid Lipofuscinosis).
    Kohlschütter A; Schulz A
    Pediatr Endocrinol Rev; 2016 Jun; 13 Suppl 1():682-8. PubMed ID: 27491216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lysosomal protein thermal stability does not correlate with cellular half-life: global observations and a case study of tripeptidyl-peptidase 1.
    Collier AM; Nemtsova Y; Kuber N; Banach-Petrosky W; Modak A; Sleat DE; Nanda V; Lobel P
    Biochem J; 2020 Feb; 477(3):727-745. PubMed ID: 31957806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extraneuronal pathology in a canine model of CLN2 neuronal ceroid lipofuscinosis after intracerebroventricular gene therapy that delays neurological disease progression.
    Katz ML; Johnson GC; Leach SB; Williamson BG; Coates JR; Whiting REH; Vansteenkiste DP; Whitney MS
    Gene Ther; 2017 Apr; 24(4):215-223. PubMed ID: 28079862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AAV gene transfer delays disease onset in a TPP1-deficient canine model of the late infantile form of Batten disease.
    Katz ML; Tecedor L; Chen Y; Williamson BG; Lysenko E; Wininger FA; Young WM; Johnson GC; Whiting RE; Coates JR; Davidson BL
    Sci Transl Med; 2015 Nov; 7(313):313ra180. PubMed ID: 26560358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.